Overview: Hepatocellular carcinoma - The future starts now

Cancer Forum

Volumn 33, Issue 2, 2009, Pages 83-87

  George, Jacob ^a   Robotin, Monica ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANCER RESEARCH DIVISION   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DISEASE COURSE; HEALTH PRACTITIONER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; METASTASIS; NONALCOHOLIC FATTY LIVER; REVIEW; VACCINATION; VIRUS HEPATITIS; VIRUS REPLICATION;

EID: 69249174649     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-285
2. Bartlett DL, Carr BI, Marsh JW. Cancers of the gastrointestinal tract: section 4: cancer of the liver. In: DeVita VJ, Hellman S, Rosenberg S, editors. Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.
3. Law MG, Roberts SK, Dore GJ, Kaldor JM. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust. 2000;173(8):403-405
4. Dore G, Wallace J, Locarnini S, Desmond P, Gane E, Crawford DH. Hepatitis B in Australia: responding to a diverse epidemic. Sydney, 2006.
5. Tracey E, Chen S, Baker D, Bishop J, Jelfs P. Cancer in New South Wales: Incidence and Mortality 2004. Sydney: Cancer Institute NSW, 2006.
6. Coates M, Tracey E. Cancer in New South Wales: Incidence and mortality 1997. NSW Public Health Bull. 2001;12(2):40-42.
7. Supramaniam R, O'Connell DL, Tracey E, Sitas F. Cancer incidence in New South Wales migrants 1991 to 2001. Sydney: The Cancer Council NSW, 2006.
8. Yuen MF. Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol. 2007;22(7):973-976. (Pubitemid 47019865)
9. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet. 2005;365(9475):1950-1956
10. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res. 2000;462(2-3):381-393 (Pubitemid 30190243)
11. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JR Jr. International trends and patterns of primary liver cancer. Int J Cancer. 2001;94(2):290-296 (Pubitemid 32911426)
12. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-3230
13. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349-1354
14. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111-21.
15. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131(3):174-181
16. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-1531 (Pubitemid 39315319)
17. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192-1199
18. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678-686 (Pubitemid 43374518)
19. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73. (Pubitemid 43042691)
20. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39(6):1076-1084
21. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417-422 (Pubitemid 39044345)
22. Rugge JB, Lochner J, Judkins D. What is the best surveillance for hepatocellular carcinoma in chronic carriers of hepatitis B? J Fam Pract. 2006;55(2):155-6; discussion 155.
23. De Masi S, Tosti ME, Mele A. Screening for hepatocellular carcinoma. Dig Liver Dis. 2005;37(4):260-268
24. Smith JB, Blumberg BS. Viral hepatitis, postnecrotic cirrhosis, and hepatocellular carcinoma. Lancet. 1969;2(7627):953.
25. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2(8256):1129-1133
26. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855-1859
27. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26(2):153-161
28. Liaw YF, Sollano JD. Factors influencing liver disease progression in chronic hepatitis B. Liver Int. 2006;26 Suppl 2:23-29
29. Tanaka Y, Mukaide M, Orito E, Yuen MF, Ito K, Kurbanov F, et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol. 2006;45(5):646-653 (Pubitemid 44466666)
30. White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008;167(4):377-89. (Pubitemid 351264139)
31. Belghiti J. Transplantation for liver tumors. Semin Oncol. 2005;32(6 Suppl 8):29-32.
32. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. N Engl J Med. 1996;334(11):693-700. (Pubitemid 26079803)
33. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236
34. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711.
35. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390